Related Experiment Video
Updated: Nov 6, 2025
05:20
Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
3.0K
5' ALK Amplification in Neuroblastoma: A Case Report
Sara Akhavanfard1, Erik Nohr2, Mohammad AlNajjar3
1Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
Case Reports in Oncology
|May 12, 2021
Summary
This case study highlights a neuroblastoma patient with complex genomic alterations. Careful interpretation of fluorescence in situ hybridization and array analysis is crucial for identifying high-risk neuroblastoma and guiding treatment.
Area of Science:
- Pediatric Oncology
- Cancer Genomics
- Molecular Diagnostics
Background:
- Neuroblastoma is a common infant cancer with variable outcomes.
- Genomic alterations like MYCN and ALK amplification indicate high-risk disease.
- Accurate genomic profiling is essential for risk stratification and treatment planning.
Observation:
- A 5-year-old male presented with metastatic neuroblastoma.
- Initial fluorescence in situ hybridization (FISH) suggested ALK gene alterations.
- Orthogonal methods revealed ALK exon gain and other unfavorable genomic features, including 17q gain and chromosome 12q amplification (CDK4, MDM2).
Findings:
- FISH findings for ALK gene alterations require careful interpretation and orthogonal validation.
- The patient exhibited multiple poor prognostic genomic markers.
- Combined genomic analysis identified complex genetic landscape in this neuroblastoma case.
Implications:
- Accurate detection of genomic alterations is critical for high-risk neuroblastoma classification.
- Advanced genomic techniques are vital for clarifying complex genetic findings.
- Precise genomic profiling aids in identifying potential therapeutic targets for neuroblastoma.
